Thalidomide in lung cancer therapy—what have we learned?

被引：0
|
作者：
Martin Reck
Ulrich Gatzemeier
机构：
[1] Hospital Grosshansdorf,Department of Thoracic Oncology
来源：
Nature Reviews Clinical Oncology | 2010年 / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Disappointing phase III results for thalidomide combined with gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer might be related to poor efficacy of targeted therapies in unselected patients. We argue that current trial designs are flawed because they expose large numbers of such patients to potentially harmful treatment, and suggest that future research strategies should prioritize identification of predictive markers.
引用
收藏
页码：134 / 135
页数：1
相关论文
共 50 条
  • [1] TARGETED THERAPIES Thalidomide in lung cancer therapy-what have we learned?
    Reck, Martin
    Gatzemeier, Ulrich
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (03) : 134 - 135
  • [2] Screening for Lung Cancer: What Have We Learned?
    Kanne, Jeffrey P.
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2014, 202 (03) : 530 - 535
  • [3] Race and Ethnicity in Cancer Therapy: What Have We Learned?
    Grenade, C.
    Phelps, M. A.
    Villalona-Calero, M. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (04) : 403 - 412
  • [4] The Genetic Epidemiology of Lung Cancer-What have we learned?
    David C.Christiani
    [J]. The Journal of Biomedical Research, 2008, (02) : 101 - 101
  • [5] Phage Therapy: What Have We Learned?
    Gorski, Andrzej
    Miedzybrodzki, Ryszard
    Lobocka, Malgorzata
    Glowacka-Rutkowska, Aleksandra
    Bednarek, Agnieszka
    Borysowski, Jan
    Jonczyk-Matysiak, Ewa
    Lusiak-Szelachowska, Marzanna
    Weber-Dabrowska, Beata
    Baginska, Natalia
    Letkiewicz, Slawomir
    Dabrowska, Krystyna
    Scheres, Jacques
    [J]. VIRUSES-BASEL, 2018, 10 (06):
  • [6] Targeted Therapy in Advanced Bladder Cancer What Have We Learned?
    Jordan, Emmet J.
    Iyer, Gopa
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2015, 42 (02) : 253 - +
  • [7] Cancer Chemoprevention: What Have we Learned?
    Yang C.S.
    Wang H.
    Dan V.
    Filippo S.S.
    [J]. Current Pharmacology Reports, 2017, 3 (6) : 409 - 422
  • [8] Cancer clusters: what have we learned?
    Stewart, B. W.
    [J]. INTERNAL MEDICINE JOURNAL, 2013, 43 (01) : 5 - 6
  • [9] CF LUNG MICROBIOME: WHAT HAVE WE LEARNED?
    Hoffman, Lucas
    [J]. PEDIATRIC PULMONOLOGY, 2013, 48 : 116 - 117
  • [10] EGFR inhibitors: what have we learned from the treatment of lung cancer?
    Giaccone, G
    Rodriguez, JA
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (11): : 554 - 561
12345